Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MID Antibodies
- Development stage
- Preclinical
- Lead developer
- M Bio Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous, Intramuscular, Topical, Oral, Inhalation, Vaginal, Ophthalmic, Rectal
01
Overview
MID Antibodies is a preclinical-stage monoclonal antibody therapeutic being developed by M Bio Technology, a Japanese research and development company focused on mycoplasma infectious diseases. The program targets Mycoplasma glycolipid antigens, which are membrane surface antigens that M Bio Technology has identified, structurally characterized, and chemically synthesized through proprietary technology. These monoclonal antibodies are designed to bind to these specific glycolipid targets to neutralize the pathogen or promote its clearance by the immune system. The primary indications for this program are infections caused by *Mycoplasma pneumoniae* and *Mycoplasma fermentans*. This development builds upon M Bio Technology's MID (Mycoplasma Infectious Diseases) platform, which also includes diagnostic and vaccine candidates, and aims to be the world's first antibody drug for mycoplasma infections.
- Other names
- Mycoplasma monoclonal antibodies
02
Targets
MGA (Mycoplasma glycolipid antigens)
Beyond the preview
Go deeper on MID Antibodies.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MID Antibodies.